Lexeo Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lexeo Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $2.45M.
- Lexeo Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $88.75M.
- Lexeo Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $88.71M, a 11.51% decline from fiscal 2023.
- Lexeo Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $100.25M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $2.45M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $88.71M 10-K · filed 2026-03-30 | |
| 2024-03-31 | $88.75M 10-Q · filed 2024-11-13 | |
| 2023-12-31 | $100.25M 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |